Kiniksa raises 2026 ARCALYST guidance, advances KPL-387 into Phase 3 pericarditis trial
The company reported Q2 2026 ARCALYST revenue of $243.6 million and said Phase 2 data on KPL-387 supported starting the pivotal PASTORALE trial, which is now enrolling patients.
SEC filing